The estimated Net Worth of Bros. Advisors Lp14159, L.P... is at least $734 Milion dollars as of 11 August 2017. Bros P owns over 176,056 units of BeiGene Ltd stock worth over $734,011,454 and over the last 7 years Bros sold BGNE stock worth over $0.
Bros has made over 1 trades of the BeiGene Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently Bros bought 176,056 units of BGNE stock worth $12,499,976 on 11 August 2017.
The largest trade Bros's ever made was buying 176,056 units of BeiGene Ltd stock on 11 August 2017 worth over $12,499,976. On average, Bros trades about 88,028 units every 0 days since 2017. As of 11 August 2017 Bros still owns at least 3,476,256 units of BeiGene Ltd stock.
You can see the complete history of Bros P stock trades at the bottom of the page.
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd.... a Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
BeiGene Ltd executives and other stock owners filed with the SEC include: